【Trading Suspension】 301096 Baicheng Pharmaceutical
【Trading Resumption】 002693 Shuangcheng Pharmaceutical
【Key Announcements】 BOE A: The company stated its main business operations are normal, with no significant changes in internal or external operating environments. After verification, there are no major undisclosed matters concerning the company, its controlling shareholder, or actual controller. Furthermore, the controlling shareholder and actual controller did not trade the company's shares during the period of abnormal stock price fluctuations.
CSG A: The company clarified it currently has no glass substrate business and derives no related revenue. It noted recent high market interest in the glass substrate concept. The company's stock price has experienced significant short-term volatility, which may involve overheated market sentiment and irrational speculation. Investors are advised to fully understand secondary market trading risks and invest prudently.
Fenglong Co., Ltd: The company disclosed it is not involved in humanoid robotics business. Its main operations remain the R&D, production, and sales of garden machinery parts, automotive parts, and hydraulic components, with no major changes. The company operates independently from UBTECH ROBOTICS and its affiliates in terms of production, operations, and core technology development. There are no other undisclosed related transactions with UBTECH ROBOTICS.
Baicheng Pharmaceutical: The company announced a planned change in control. Its controlling shareholders and actual controllers are planning a major event that may change company control. To ensure fair information disclosure and prevent abnormal stock price volatility, trading of the company's shares will be suspended starting from the market open on May 25, 2026, for an expected period not exceeding two trading days.
Zhengchuan Co., Ltd: The company's controlling shareholder, Zhengchuan Investment, plans to transfer 15.12 million shares (10% of total shares) via a block transfer to Beijing Anjing Licheng Health Technology Partnership for a total consideration of 299 million yuan. This transfer does not involve a change in company control. The transferee made the investment based on recognition of the long-term prospects of the pharmaceutical health industry and the company's intrinsic value.
【Shareholding Changes】 Rainbow Group: The company received a shareholding change report from Wan Liujun, Huang Hongyou, and Wan Xing. As of the report date, these parties have cumulatively increased their holdings to 6.54 million shares, representing 6.21% of total shares. They constitute persons acting in concert. They failed to promptly disclose the change when their combined holdings reached 5% on April 16, 2026, due to insufficient understanding of relevant regulations.
Jindun Co., Ltd: Shareholder Fangzheng Securities, holding 3.55%, plans to reduce its holdings by up to 12.20 million shares (3% of total shares) through block trades and centralized bidding.
Fute Technology: Shareholder Changgao Dianxin, holding 4.66%, plans to reduce its holdings by up to 5.02 million shares (3% of total shares) through centralized bidding and block trades.
Kangzhong Medical: Actual controller and senior executive Gao Peng, holding 4.66%, plans to reduce holdings by up to 1.02 million shares (1.16% of total shares) between June 15, 2026, and September 14, 2026, via centralized bidding and block trades.
Dongwei Semiconductor: Shareholder Deshu Jucai plans to reduce holdings by 1.13 million shares (0.92% of total shares) via block trade on behalf of a limited partner withdrawing from the partnership. Company actual controller and Chairman Gong Yi is not involved in this reduction.
【Major Contracts】 Dajin Heavy Industry: A subsidiary signed a shipbuilding contract with a Dutch shipowner for approximately 1.056 billion yuan (about $156 million). The contract involves the design, construction, and delivery of two 25,000 DWT multi-purpose heavy lift vessels, scheduled for completion and delivery in 2028 and 2029.
【Other Announcements】 Aidi Pharmaceutical: A wholly-owned subsidiary received approval from the National Medical Products Administration for the marketing application of the active pharmaceutical ingredient Darunavir. Darunavir is an HIV-1 protease inhibitor used in combination therapy for HIV patients.
Lianchuang Electronic: The company stated its operations are normal with no significant changes in its operating environment. After inquiry, there are no undisclosed major matters concerning the company, its controlling shareholder, or actual controller. The controlling shareholder and actual controller did not trade shares during the period of abnormal stock price fluctuations.
Titan Co., Ltd: The company clarified that its high-end electronic fabric jet loom is still in the R&D phase. The project has a long development cycle and faces significant challenges in core component development, with risks of R&D failure and inability to achieve industrialization or profitability. It will not have any impact on the company's near-term operating performance.
Hetai Electromechanical: The company clarified it is not involved in the production or manufacturing of robots or related components. Its main business is the R&D, design, manufacturing, and sales of material conveying equipment, primarily used in industries like cement, building materials, ports, steel, and chemicals.
Keyuan Wisdom: The company noted significant market attention on power demand driven by AIDC construction, industrial AI applications, and the gas turbine industry. While the company is a leader in domestic gas turbine combined cycle power unit control systems, related business currently constitutes a small proportion of its operating revenue and has limited short-term impact on performance, with significant uncertainty regarding sustainability and profit contribution. Similarly, its industrial robotics-related business also represents a small portion of revenue.
Comments